Published online May 1, 2007
PEDIATRICS Vol. 119 No. 5 May 2007, pp. 936-940 (doi:10.1542/peds.2006-2986)

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My File Cabinet Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Natarajan, G. Articles by Aranda, J. V. Search for Related Content PubMed PubMed Citation Articles by Natarajan, G. Articles by Aranda, J. V. Related Collections Therapeutics & Toxicology Social Bookmarking                         What's this?

ARTICLE

Therapeutic Drug Monitoring for Caffeine in Preterm Neonates: An Unnecessary Exercise?

Girija Natarajan, MD^a, Mirjana-Lulic Botica, BS, RPh^b, Ronald Thomas, PhD^c and Jacob V. Aranda, MD, PhD^d

^a Divisions of Neonatology
^c Biostatistics
^d Clinical Pharmacology and Toxicology and the Pediatric Pharmacology Research Unit, Children's Hospital of Michigan, Detroit, Michigan
^b Department of Pharmacy, Hutzel Women's Hospital, Detroit, Michigan

OBJECTIVE. Our goal was to determine the value of measuring plasma caffeine levels in preterm neonates treated with caffeine for apnea. We evaluated plasma concentrations of caffeine attained in preterm neonates at standard doses, at varying postconceptual ages, with renal or hepatic dysfunction and when there was clinical lack of efficacy. We hypothesized that measurement of plasma caffeine concentrations during apnea therapy is not clinically helpful.

PATIENTS/METHODS. An observational study was conducted at Hutzel Women's Hospital between January 2000 and September 2005. Preterm neonates who were being treated with caffeine and who had a plasma caffeine level measured on at least 1 occasion were included.

RESULTS. A total of 231 caffeine blood levels were obtained from 101 preterm neonates with a median gestation of 28 weeks (range: 23–32 weeks) and birth weight of 1030 g (range: 540–2150 g). The caffeine citrate dose used ranged form 2.5 to 10.9 mg/kg (median: 5 mg/kg), and the levels ranged from 3.0 to 23.8 mg/L. Levels were between 5.1 and 20 mg/L in 94.8%, <5 mg/L in 2.1%, and >20 mg/L in 3.1%. Levels in the 5.1 to 20 mg/L range were attained on 91.3% of occasions when there was concomitant renal dysfunction (n = 23) and in all cases of hepatic dysfunction (n = 13). The median (25th, 75th quartiles) levels drawn for lack of efficacy (14.1 [10.2, 8.3] mg/L; n = 94) were comparable to those obtained for routine monitoring (13.7 [11, 9] mg/L; n = 107).

CONCLUSIONS. A majority of preterm neonates attain plasma caffeine levels between 5 and 20 mg/L, independent of gestation. This observation held even for the small number of subjects with elevated blood urea nitrogen, serum creatinine, or liver enzyme levels. Therapeutic drug monitoring is not necessary when caffeine is used for the treatment of apnea of prematurity in neonates.

---

Key Words: caffeine • methylxanthine • apnea • therapeutic drug monitoring

Abbreviations: PCA—postconceptional age • BUN—blood urea nitrogen

---

Accepted Dec 29, 2006.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Caffeine for Apnea -- Why Check the Level? Journal Watch Pediatrics and Adolescent Medicine, June 6, 2007; 2007(606): 2 - 2. [Full Text]